A role of p38 mitogen-activated protein kinase in adenosine A1 receptor-mediated synaptic depotentiation in area CA1 of the rat hippocampus by Liang, Ying-Ching et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Molecular Brain
Open Access Research
A role of p38 mitogen-activated protein kinase in adenosine A1 
receptor-mediated synaptic depotentiation in area CA1 of the rat 
hippocampus
Ying-Ching Liang2, Chiung-Chun Huang1 and Kuei-Sen Hsu*1,2
Address: 1Department of Pharmacology, College of Medicine, National Cheng Kung University, No. 1, University Road, Tainan City 701, Taiwan 
and 2Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, No. 1, University Road, Tainan City 701, Taiwan
Email: Ying-Ching Liang - alice217@ms35.url.com.tw; Chiung-Chun Huang - Chun19680111@yahoo.com.tw; Kuei-
Sen Hsu* - richard@mail.ncku.edu.tw
* Corresponding author    
Abstract
Background:  Although long-term potentiation (LTP) of synaptic strength is very persistent,
current studies have provided evidence that various manipulations or pharmacological treatment
when applied shortly after LTP induction can reverse it. This kind of reversal of synaptic strength
is termed as depotentiation and may have a function to increase the flexibility and storage capacity
of neuronal networks. Our previous studies have demonstrated that an increase in extracellular
levels of adenosine and subsequent activation of adenosine A1 receptors are important for the
induction of depotentiation; however, the signaling downstream of adenosine A1 receptors to
mediate depotentiation induction remains elusive.
Results: We confirm that depotentiation induced by low-frequency stimulation (LFS) (2 Hz, 10
min, 1200 pulses) was dependent on adenosine A1 receptor activation, because it was mimicked by
bath-applied adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) and was inhibited by
the selective adenosine A1  receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX).
Pretreatment of the hippocampal slices with the selective p38 mitogen-activated protein kinase
(MAPK) inhibitors, 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl]-5-(4-pyrudyl)-1H-imidazole
(SB203580) or trans-1-(4-hydroxycyclohexyl)-4-(fluorophenyl)-5-(2-methoxypyrimidin-4-
yl)imidazole (SB239063), prevented the induction of depotentiation by LFS and CPA. In agreement
with electrophysiological observation, both LFS- and CPA-induced depotentiation are associated
with an increase in p38 MAPK activation, which are blocked by DPCPX or SB203580 application.
Conclusion: These results suggest that activation of adenosine A1 receptor and in turn triggering
p38 MAPK signaling may contribute to the LFS-induced depotentiation at hippocampal CA1
synapses.
Background
Long-term potentiation (LTP) is a long-lasting form of
activity-dependent synaptic plasticity that is generally
thought to play crucial roles in learning and memory
processes in the brain [1,2]. Although LTP is remarkable
for its stability, numerous studies have revealed that it is
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initially labile and sensitive to disruption by a variety of
interfering events and agents [3,4]. Such reversal of synap-
tic strength from the potentiated state to pre-LTP levels
has been termed depotentiation and may provide a mech-
anism of preventing the saturation of the synaptic poten-
tiation and increase the efficacy and the capacity of the
information storage of the neuronal networks [3].
A sustained train of low-frequency stimulation (LFS) is a
powerful paradigm for studying the molecular mecha-
nism underlying the induction of depotentiation. Previ-
ous work from our and other laboratories have
demonstrated that trains of 1–5 Hz LFS can produce an
enduring and complete reversal of synaptic potentiation
when delivered within 10 min of LTP induction [1,3,5,6].
So far, a number of synaptic signaling molecules have
been identified that participates in the induction of depo-
tentiation including adenosine, calcineurin, nitric oxide,
and small GTPase Rap2 [6-12]. Less well understood are
the processes that control signaling from these synaptic
ligands and receptors. For example, we have previously
proposed that the reversal of LTP at the Schaffer collateral-
CA1 synapses by LFS is associated with an increase of
extracellular levels of adenosine acting on adenosine A1
receptor to interrupt the cAMP/protein kinase A (PKA)-
dependent biochemical processes leading to LTP [6,11].
We further demonstrated that the efflux of cAMP is the
potential source for the increased extracellular adenosine
underlying LFS-induced depotentiation [6]. However, it is
still unclear the signaling downstream of adenosine A1
receptors to mediate the induction of LFS-induced depo-
tentiation. Recent data suggest that p38 mitogen-activated
protein kinase (MAPK) activation may contribute to ade-
nosine A1 receptor-mediated synaptic depression in the
hippocampal CA1 region [13]. Moreover, p38 MAPK sig-
naling has been shown to be an important mediator of
AMPA receptor surface trafficking during synaptic plastic-
ity, a process crucial for rapid altering synaptic strength
[14,15]. It became, therefore, of interest to study possible
roles of p38 MAPK in adenosine A1 receptor-mediated
depotentiation.
Here, we tested whether p38 MAPK signaling is involved
in the induction of LFS-induced depotentiation in the
CA1 region of hippocampus. Our study provides evidence
that p38 MAPK may serve as a signaling downstream of
adenosine A1 receptor activation to induce depotentia-
tion.
Results
p38 MAPK contributes to LFS-induced depotentiation
Using field potential recordings, we first tested for the
existence of a LFS-induced depotentiation in the CA1
region of hippocampal slices. LTP was induced by two 1-
sec trains of 100 Hz stimuli separated by intertrain inter-
val of 20 sec. The mean slope of the field excitatory posts-
ynaptic potential (fEPSP) measured 50 min after high-
frequency tetanic stimulation (HFS) was 146.5 ± 4.2% (n
= 8) of baseline (Fig. 1A). To establish a reliable depoten-
tiation, a long train of LFS protocol, 2 Hz/1200 pulse
stimulation, was used [6,16]. As expected, when LFS was
applied 5 min after LTP induction, LTP was almost com-
pletely reversed (Fig. 1A). The mean residual potentiation
measured 40 min after the end of LFS was 96.5 ± 5.8% (n
= 8) of baseline. Thus, these results generally confirmed
previous studies showing that LTP is vulnerable to disrup-
tion by depotentiation stimuli within a short period after
its induction [6,17,18].
To assess the role of p38 MAPK in the induction of LFS-
induced depotentiation, the highly selective p38 MAPK
inhibitor 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl]-
5-(4-pyrudyl)-1H-imidazole (SB203580) was used. As
shown in Figure 1B, SB203580 (1 μM) treatment alone
had no effect on the induction of LTP. The mean slope of
the fEPSP measured 50 min after HFS was 153.6 ± 8.5%
(n = 6) of baseline, which was not statistically different
from the corresponding values of control slices. In marked
contrast to control slices, application of LFS, 5 min after
LTP induction, failed to induce depotentiation in all eight
slices tested. The mean residual potentiation measured 40
min after the end of LFS was 138.5 ± 6.2% (n = 8) of base-
line (Fig. 1B). To further confirm a role of p38 MAPK in
the induction of depotentiation, in another set of experi-
ments, we examined the effect of another 38 MAPK inhib-
itor  trans-1-(4-hydroxycyclohexyl)-4-(fluorophenyl)-5-
(2-methoxypyrimidin-4-yl)imidazole (SB239063) on the
LFS-induced depotentiation. We found that application of
SB239063 (1 μM) failed to affect the LTP induction
(148.5 ± 8.1% of baseline, n = 4; p > 0.05 when compared
with control LTP slices; unpaired Student's t test), but pre-
vented the LFS-induced depotentiation (Fig. 1C). The
mean residual potentiation measured 40 min after the
end of LFS was 139.5 ± 7.5% (n = 5) of baseline. In addi-
tion, in both control and SB203580-treated slices, 10 min
of 2 Hz stimulation delivered to Schaffer collateral-CA1
synapses had no long-lasting effect on the synaptic trans-
mission (Fig. 1D). The mean slope of the fEPSP measured
40 min after the end of LFS was 96.5 ± 6.7% (n = 6) and
98.3 ± 7.2% (n = 6) of baseline, respectively. Similar
results were also obtained using an antibody that selec-
tively recognizes phosphorylated, activated p38 MAPK
[19]. As shown in Figure 1E, phospho-p38 MAPK was
readily detected in untreated control slices, and the levels
were increased to 132.5 ± 6.8% (n = 5) of control in LFS
(2 Hz)-treated slices. However, no significant changes in
the levels of phospho-p38 MAPK were observed 30 min
after LTP induction (102.8 ± 5.6% of control slices, n = 5;
p > 0.05; unpaired Student's t test). In LFS-induced depo-
tentiation experiments, we found that there was signifi-Molecular Brain 2008, 1:13 http://www.molecularbrain.com/content/1/1/13
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Figure 1 (see legend on next page)
Time (min)
- 1 00 1 02 03 04 05 06 0
 
 
 
f
E
P
S
P
 
s
l
o
p
e
 
(
%
 
o
f
 
b
a
s
e
l
i
n
e
)
0
50
100
150
200
250
2 Hz
3
2
HFS 1 4
1
0.5 mV
2
3
4
10 ms
Time (min)
- 1 00 1 02 03 04 05 06 0
 
 
 
f
E
P
S
P
 
s
l
o
p
e
 
(
%
 
o
f
 
b
a
s
e
l
i
n
e
)
0
50
100
150
200
2 Hz 3 2
1
4
(    ) Vehicle or (    ) SB203580
3
0.5 mV
10 ms
4
1
2
A
D
Time (min)
- 1 00 1 02 03 04 05 06 0
 
 
 
f
E
P
S
P
 
s
l
o
p
e
(
%
 
o
f
 
b
a
s
e
l
i
n
e
)
0
50
100
150
200
250
2 Hz
3
2
HFS
4
1
SB203580
2
1 3
4
0.5 mV
10 ms
B
E
P-p38
%
 
P
h
o
s
p
h
o
r
y
l
a
t
i
o
n
0
50
100
150
200
(n = 5)
Con
2 HZ
LTP
DEP
Con
2 HZ
DEP
SB203580
p38
z
Time (min)
-10 0 10 20 30 40 50 60
 
 
 
f
E
P
S
P
 
s
l
o
p
e
(
%
 
o
f
 
b
a
s
e
l
i
n
e
)
0
50
100
150
200
250
2 Hz
3
2
HFS
4
1
SB239063
2
1 3
4
0.5 mV
10 ms
CMolecular Brain 2008, 1:13 http://www.molecularbrain.com/content/1/1/13
Page 4 of 9
(page number not for citation purposes)
cant increased the levels of phospho-p38 MAPK (134.2 ±
7.2% of control slices, n = 5; p < 0.05; unpaired Student's
t  test). In addition, pretreatment of the slices with
SB203580 (1 μM) completely blocked the increase in p38
MAPK phosphorylation induced by LFS (Fig. 1E). These
results strongly support the view that the p38 MAPK is an
obligatory component of the biochemical bases that
serves the induction of LFS-induced depotentiation.
Adenosine A1 receptor-mediated depotentiation was 
decreased by p38 MAPK inhibition
We and other laboratories have previously shown that an
increase of extracellular adenosine acting on adenosine A1
receptors may be a component of the mechanism that
triggers LFS-induced depotentiation in the hippocampal
CA1 region [6,8,18]. A recent study has revealed that ade-
nosine A1  receptor-mediated synaptic depression is
dependent on p38 MAPK activation [13]. It was therefore
of interest to examine the relationship between p38
MAPK activation and adenosine-mediated signaling path-
ways in the induction of depotentiation. We began by
confirming that LFS-induced depotentiation can be
blocked by the selective adenosine A1 receptor antagonist
8-cyclopentyl-1,3-dipropylxanthine (DPCPX). As shown
in Figure 2A, the LFS-induced depotentiation was signifi-
cantly inhibited in the presence of DPCPX (0.1 μM). The
slope of fEPSP after LFS recovered close to the initial LTP
levels. The mean residual potentiation measured 40 min
after the end of LFS was 140.9 ± 8.6% (n = 5) of baseline.
Application of DPCPX alone had no significant effect on
the induction of LTP (149.7 ± 7.5% of baseline, n = 6; p >
0.05; unpaired Student's t test).
We next tested whether the reversal of LTP induced by a
direct adenosine application was also affected by p38
MAPK antagonism. Because adenosine may act at multi-
ple receptor subtypes and is rapidly degraded by ecto-
nucleotidases [20], we used the specific adenosine A1
receptor agonist N6-cyclopentyladenosine (CPA) to
address this issue. Application of CPA (0.2 μM) for 5 min
potentially depressed the fEPSP by 84.5 ± 6.5% of base-
line (n = 6). The fEPSP fully recovered after washout of
drug (Fig. 2B). We next examined the effect of CPA appli-
cation on the previously established LTP. In agreement
with our previous findings [6,11], CPA (0.2 μM for 5 min)
applied 5 min after LTP induction almost completely
reversed LTP (Fig. 2C). The mean residual potentiation
measured 40 min after washout of CPA was 98.9 ± 7.2%
(n = 6) of baseline. When CPA was applied in the presence
of DPCPX (0.1 μM), both acute response and the resulting
depotentiation were inhibited significantly (Fig. 2C). The
mean residual potentiation measured 40 min after wash-
out of CPA was 142.3 ± 6.5% (n = 6) of baseline. In addi-
tion, we tested the effect of SB203580 and SB239063 on
the induction of depotentiation by CPA. As shown in Fig-
ure 2D, treatment of either SB203580 (1 μM) or
SB239063 (1 μM) had little effect on the acute response
during CPA application but significantly blocked the
induction of CPA-induced depotentiation. The mean
residual potentiation measured 40 min after washout of
CPA was 136.5 ± 6.7% (n = 6) and 132.3 ± 7.4% (n = 4)
of baseline, respectively. In addition, pretreatment of the
slices with DPCPX (0.1 μM) completely blocked the
increase in p38 MAPK phosphorylation induced by LFS
(Fig. 2E). Figure 2F shows that substantial increase in the
levels of phospho-p38 MAPK is evident in CPA-induced
depotentiation slices. Pretreatment of either DPCPX (0.1
μM) or SB203580 (1 μM) for 20 min also blocked the
increase in p38 MAPK phosphorylation induced by CPA.
Together, these results suggest that p38 MAPK seems to be
the downstream signaling molecule for adenosine A1
receptor activation to induce depotentiation.
Discussion
In this study, we identify a novel interaction between ade-
nosine A1 receptor and p38 MAPK in hippocampal neu-
p38 MAPK contributes the induction of LFS-induced depotentiation Figure 1 (see previous page)
p38 MAPK contributes the induction of LFS-induced depotentiation. (A) Summary of experiments showing that LFS 
(2 Hz, 10 min) given 5 min after two trains of 100 Hz HFS almost completely reversed LTP (n = 8; ❍), whereas fEPSPs in slices 
that received HFS without LFS exhibited persistent potentiation (n = 8; ●). (B) Summary of experiments showing that pre-
treatment of slices with the p38 MAPK inhibitor SB203580 (1 μM) blocked the induction of LFS-induced depotentiation (n = 8; 
●) but had no effect on the induction of LTP (n = 6; ❍). (C) Summary of experiments showing that pretreatment of slices with 
the p38 MAPK inhibitor SB239063 (1 μM) blocked the induction of LFS-induced depotentiation (n = 5; ●) but had no effect on 
the induction of LTP (n = 4; ❍). (D) Summary of experiments showing that the protocol of LFS had no lasting effect on synap-
tic transmission in the presence of vehicle (n = 6; ❍) or SB203580 (n = 6; ●). The superimposed fEPSP in the inset illustrates 
respective recordings from example experiments taken at the time indicated by number. Horizontal bars denote the period of 
delivery LFS or SB203580. (E) Representative immunoblots showing that the induction of LFS-induced depotentiation (DEP) is 
accompanied by a significant increase in p38 MAPK phosphorylation and that SB203580 (1 μM) prevented this enhancement 
action. Group data showing the normalization of phospho-p38 MAPK to the nonphosphorylated form was determined in each 
group of five experiments. In each experiment, 21–28 slices obtained from 2–3 rats were used. *, p < 0.05 (unpaired Student's 
t test) as compared with the control (Con) group.Molecular Brain 2008, 1:13 http://www.molecularbrain.com/content/1/1/13
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Figure 2 (see legend on next page)
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rons. We have shown that activation of adenosine A1
receptors, either by a train of LFS or a brief application of
adenosine A1 receptor agonist CPA, can trigger a depoten-
tiation by a mechanism that requires the activation of p38
MAPK signaling pathway.
A number of studies have revealed an important role for
extracellular adenosine acting on adenosine A1 receptors
in mediating the induction of depotentiation [6,8,11,18].
However, the signaling downstream of adenosine A1
receptor activation to trigger depotentiation remains elu-
sive. We have previously shown that activation of adeno-
sine A1 receptor may interrupt the cAMP-PKA-dependent
biochemical processes associated with the LTP expression
[6,11]. Here, we have extended these findings by demon-
strating that p38 MAPK may lie downstream of adenosine
A1 receptor activation to induce depotentiation. Evidence
supporting this prediction is that pretreatment of the hip-
pocampal slices with the specific p38 MAPK inhibitors,
SB203580 and SB239063, effectively prevented the induc-
tion of depotentiation by LFS and CPA. We further show
that the induction of LFS- or CPA-induced depotentiation
also leaded to a significant increase in the levels of p38
MAPK phosphorylation and these effects were prevented
by prior treatment of the hippocampal slices with adeno-
sine A1 receptor antagonist. Such a result is in line with the
recent observation that p38 MAPK activation contributes
to adenosine A1 receptor-mediated synaptic depression at
Schaffer collateral-CA1 synapses [13].
The induction and expression of depotentiation involve
multiple cellular and molecular mechanisms [3,4]. A
number of studies indicate that the induction of depoten-
tiation relies on synaptic activation of NMDA receptors
[5,11,21] or metabotropic glutamate (mGlu) receptors
[22-24]. We have previously shown that hippocampal
CA1 depotentiation induced by LFS (2 Hz, 10 min, 1200
pulses) is dependent on NMDA receptor activation [11].
We further showed that activation of NMDA receptors
may stimulate adenosine-mediated signaling pathways to
trigger depotentiation [11]. In this study, we have
extended theses findings by showing that p38 MAPK
could act downstream of adenosine A1 receptor activation
to undergo the induction of depotentiation. The role of
mGlu receptors in the induction of depotentiation
remains controversial, largely because some groups have
been unable to replicate the findings that mGlu receptors
are necessary for depotentiation induction under their
experimental conditions [25]. The reason for this discrep-
ancy is not clear but could be attributable partly to the use
of different depotentiating stimulation protocols. Because
the ability of LFS used in the present study to erase LTP
was not significantly affected by either non-selective
mGlu antagonist α-methyl-4-carboxyphenylglycine
(MCPG) or selective group 1 mGlu receptor antagonist
2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-
9-yl)-propanoic acid (LY341495) treatment (Huang and
Hsu unpublished observation), we suggest that the activa-
tion of mGlu receptors is not required for the LFS-induced
depotentiation in the hippocampal CA1 region.
How might adenosine A1 receptors stimulation lead to
p38 MAPK activation? The signal transduction events that
couple adenosine A1 receptor stimulation to p38 MAPK
activation were not examined here. A previous study in
the smooth muscle cell line has indicated that p38 MAPK
can be activated by the adenosine A1 receptors via a per-
tussis toxin-sensitive signaling pathway [26]. It seems
likely that the p38 MAPK activation by the adenosine A1
receptors is mediated by Gi/o proteins coupling to classical
intracellular signaling pathways such as modulation of
cAMP production or the phospholipase C pathway
Application of p38 MAPK inhibitor prevented the induction of adenosine A1 receptor-mediated depotentiation Figure 2 (see previous page)
Application of p38 MAPK inhibitor prevented the induction of adenosine A1 receptor-mediated depotentia-
tion. (A) Summary of experiments showing that pretreatment of slices with the adenosine A1receptor antagonist DPCPX (0.1 
μM) blocked the induction of LFS-induced depotentiation (n = 5; ●) but had no effect on the induction of LTP (n = 6; ❍). (B) 
Summary of experiments showing that application of CPA (0.2 μM) for 5 min produced a depression of fEPSPs (n = 6; ❍). The 
fEPSP fully recovered after washout of drug. (C) Summary of experiments showing that CPA (0.2 μM; 5 min) given 5 min after 
two trains of 100 Hz HFS almost completely reversed LTP (n = 6; ❍). Note that CPA-induced depotentiation was completely 
blocked by DPCPX (n = 6; ●). (D) Summary of experiments showing that pretreatment of slices with SB203580 (1 μM, n = 6; 
❍) or SB239063 (1 μM, n = 4; ●) blocked the CPA-induced depotentiation. (E) Representative immunoblots showing that the 
induction of LFS-induction depotentiation (DEP) is accompanied by a significant increase in p38 MAPK phosphorylation and 
that DPCPX prevented this enhancement action. Group data showing the normalization of phospho-p38 MAPK to the non-
phosphorylated form was determined in each group of four experiments. In each experiment, 21–28 slices obtained from 2–3 
rats were used. (F) Representative immunoblots showing that the induction of CPA-induced depotentiation (CPA-DEP) is 
accompanied by a significant increase in p38 MAPK phosphorylation. Note that CPA-induced increase in p38 MAPK phosphor-
ylation was significantly blocked by DPCPX or SB203580. Group data showing the normalization of phospho-p38 MAPK to the 
nonphosphorylated form was determined in each group of five experiments. In each experiment, 15–20 slices obtained from 2 
rats were used. *, p < 0.05 (unpaired Student's t test) as compared with the control (Con) group.Molecular Brain 2008, 1:13 http://www.molecularbrain.com/content/1/1/13
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[27,28]. Interestingly, several other studies have reported
that G protein-coupled receptors can also activate p38
MAPK via Gβγ subunits. For example, in human embry-
onic kidney 293 cells, Gi-coupled m2 muscarinic recep-
tors and Gs-coupled β-adrenergic receptors were found to
stimulate p38 MAPK via Gβγ [29]. Similarly, our previous
study has also demonstrated that by releasing Gβγ subu-
nits, the Gq/11-coupled type 5 metabotropic glutamate
receptors can activate small GTPase Rap1 to mediate (S)-
3,5-dihydroxyphenylglycine (DHPG)-induced p38 MAPK
activation in hippocampal CA1 neurons [15]. According
to these previous observations, it will be important for
future studies to identify which of these mechanisms is
responsible for the adenosine A1 receptor-mediated p38
MAPK activation observed in hippocampal CA1 neurons.
How might p38 MAPK activation reverse the previously
established LTP? A most likely possibility is that a decrease
in the surface expression of AMPA receptors contributes to
this process. Activity-dependent changes in AMPA recep-
tor trafficking have been proposed to play a critical role in
mediating bidirectional synaptic plasticity [30,31]. It has
been shown that LTP induction in hippocampal slices is
associated with an increase in the delivery of AMPA recep-
tors to dendritic spines [32,33], whereas the expression of
LTD is associated with a decrease in the surface expression
of AMPA receptors [34,35]. With the use of biochemical
surface biotinylation assay, we have previously shown
that the expression of DHPG-induced depotentiation is
associated with a reduction in the increase of the surface
expression of AMPA receptors seen with LTP [24]. This
finding strongly implies that the removal of synaptic sur-
face AMPA receptor is a potential mechanism underlying
the expression of depotentiation in hippocampal neu-
rons. In addition, previous work from our and other lab-
oratories has demonstrated that activation of p38 MAPK
may lead to synaptic removal of surface AMPA receptors
[12,15]. These results suggest that p38 MAPK-mediated
synaptic removal of surface AMPA receptors may account
for, at least in part, the development of adenosine A1
receptor-dependent form of depotentiation. Our previous
studies have found that the expression of LFS-induced
depotentiation was accompanied by a persistent dephos-
phorylation of the GluR1 subunit of AMPA receptors at
serine 831, a protein kinase C and calcium/calmodulin-
dependent protein kinase II substrate, but not at serine
845, a substrate of PKA [6,11]. Activation of protein phos-
phatase 1 (PP1) triggered this dephosphorylation (Huang
et al., 2001) and inhibition of PP1 activity rendered the
depotentiation stimuli ineffective [6,36]. Taken together,
these findings indicate that the interaction between p38
MAPK and PP1 can determine whether depotentiation is
induced at Schaffer collateral-CA1 synapses.
Our results indicate that SB203580 produced only little
effect on the acute response during CPA application but
significantly blocked the induction of CPA-induced depo-
tentiation. This finding is in contrast with observation
made in a previous study [13], which reported that
SB203580 potently reduced CPA-mediated synaptic
depression. The reason for this discrepancy is not clear. It
remains to be determined if the use of different concentra-
tions of CPA (0.2 μM vs. 40 nM) and SB203580 (1 μM vs.
25 μM) has a role in explaining the conflicting results. In
addition, SB203580 has been shown to effectively com-
pete the binding of adenosine A1  receptor antagonist
DPCPX in rat brain membrane at micromolar concentra-
tions [37]. Given that the concentration of SB203580
used in this study was below the effective concentration as
adenosine A1  receptor antagonist [37], we therefore
assumed that the effect of SB203580 on depotentiation
was mediated via the inhibition of p38 MAPK.
An intriguing observation of this study is that 2 Hz stimu-
lation alone in control slices significantly increased the
levels of phospho-p38 MAPK but had no long-lasting
effect on the basal synaptic transmission (Fig. 1D, 1E and
2E). A plausible explanation for this finding may be that
p38 MAPK activity is required but is not sufficient for the
induction of synaptic depotentiation or depression. How-
ever, further experiments are required to test this possibil-
ity.
Conclusion
In summary, we have shown in this study that p38 MPAK
is activated by adenosine A1 receptor stimulation and con-
tributes to the induction of depotentiation in the hippoc-
ampal CA1 region. Given the potential role of LTP in
learning and memory formation and the processes dis-
rupting the formation of stable LTP may be the possible
cause for the loss of memory [1,3], our findings imply a
possibility that p38 MAPK is a potential common signal-
ing molecule to exert the mechanism of memory loss. It
would be interesting to explore whether the selective p38
MAPK inhibitor may be implicated in enhancing cogni-
tion in the treatment of some dementia disorders.
Methods
Hippocampal slice preparation
All procedures were performed according to NIH guide-
lines for animal research (Guide for the Care & Use of Lab-
oratory Animals, NRC, 1996) and approved by the
Institutional Animal Care and Use Committee at National
Cheng Kung University. Hippocampal slices were
obtained from 28- to 35-day old young male Sprague-
Dawley rats for extracellular recordings by the procedures
described previously [6]. In brief, animals were anesthe-
tized with halothane and decapitated with guillotine, and
the hippocampi were removed, placed in ice cold artificialMolecular Brain 2008, 1:13 http://www.molecularbrain.com/content/1/1/13
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CSF (aCSF) solution and cut with a Leica VT1000S tissue
slicer (Leica, Nussloch, Germany) into transverse slices of
400 μm. After their preparation, slices were placed in a
holding chamber of aCSF oxygenated with 95% O2-5%
CO2 and kept at room temperature for at least 1 h before
used. The composition of the aCSF solution was (in mM):
NaCl 117, KCl 4.7, CaCl2 2.5, MgCl2 1.2, NaHCO3 25,
NaH2PO4 1.2 and glucose 11 at pH 7.3–7.4 and equili-
brated with 95% O2-5% CO2.
Electrophysiological recordings
For the extracellular field potential recordings, a single
slice was transferred to a submerge-type recording cham-
ber and held between two nylon nets. The chamber con-
sisted of a circular well of a low volume (1–2 ml) and was
continuously perfused with oxygenated aCSF at a flow
rate of 2–3 ml/min at 32.0 ± 0.5°C. Area CA3 was surgi-
cally removed after sectioning. Extracellular field poten-
tial recordings were carried out using an Axoclamp-2B
amplifier (Axon Instruments, Union City, CA). Microelec-
trodes were pulled from microfibre 1.0 mm capillary tub-
ing on a Brown-Flaming electrode puller (Sutter
Instruments, San Rafael, CA). The responses were low pass
filtered at 2 kHz, digitally sampled at 5–10 kHz, and ana-
lyzed using pCLAMP software (Version 7.0; Axon Instru-
ments). The evoked postsynaptic responses were induced
in CA1 stratum radiatum by stimulation (0.02 ms dura-
tion) of Schaffer collateral/commissural afferents at 0.033
Hz with a bipolar stainless steel stimulating electrode. The
stimulation strength was set to elicit a response having
amplitude that was 30–40% of the maximum spike-free
response. fEPSPs were recorded with a glass pipette filled
with 1 M NaCl (2–3 MΩ resistance) and fEPSP slope was
measured from approximately 20–70% of the rising phase
using a least-squares regression. The LTP was induced by
HFS, at the test pulse intensity, consisting of two 1-sec
trains of stimuli separated by an intertrain interval of 20
sec at 100 Hz. Depotentiation was induced by application
of 10 min low-frequency trains of stimuli at 2 Hz, and the
stimulation intensity was the same as the test pulse inten-
sity. All values of residual potentiation reported here were
calculated as the changes in the slope of fEPSPs measured
40 min after the end of LFS.
Western blotting
Hippocampal slices were prepared and treated with HFS
with or without LFS exactly as described in the electro-
physiological experiments. At the end of experiments, the
CA1 subregion of the hippocampal slices between the
positions of the stimulating and recording electrodes was
dissected out and immediately frozen on dry ice. Three to
four microdissected CA1 subregions (from control, 30
min after LTP induction, 15 min after the end of LFS, 20
min after washout of CPA) were pooled together. In each
experiment, an entire set of control, LTP, or depotentia-
tion pooled slices was taken from one animal. The micro-
dissected subregions were lysed in ice-cold Tris-HCl buffer
solution (TBS; pH 7.4) containing a cocktail of protein
phosphatase and proteinase inhibitors (50 mM Tris-HCl,
100 mM NaCl, 15 mM sodium pyrophosphate, 50 mM
sodium fluoride, 1 mM sodium orthovanadate, 5 mM
EGTA, 5 mM EDTA, 1 mM phenylmethylsulfonyl fluo-
ride, 1 μM microcystin-LR, 1 μM okadaic acid, 0.5% Tri-
ton X-100, 2 mM benzamidine, 60 μg/ml aprotinin, and
60 μg/ml leupeptin) to avoid dephosphorylation and deg-
radation of proteins, and ground with a pellet pestle
(Kontes glassware, Vineland, NJ, USA). Samples were son-
icated and spun down at 15,000 × g at 4°C for 10 min.
The supernatant was then assayed for total protein con-
centration using Bio-Rad Bradford Protein Assay Kit (Her-
cules, CA). Each sample was separated in 10% SDS-PAGE
gel. Following the transfer on PVDF membranes, blots
were blocked in buffer solution containing 5% milk and
0.1% Tween-20 in PBS (124 mM NaCl, 4 mM KCl, 10 mM
Na2HPO4, and 10 mM KH2PO4, pH 7.2) for 1 h and then
blotted for 2 h at room temperature with antibodies that
recognize phosphorylated p38 MAPK (1:1000; New Eng-
land BioLabs, Beverly, MA). It was then probed with HRP-
conjugated secondary antibody for 1 h and developed
using the ECL immunoblotting detection system (Amer-
sham Biosciences, Buckinghamshire, UK), according to
manufacturer's instructions. The immunoblots using
phosphorylation site-specific antibodies were subse-
quently stripped and reprobed with an antibody that rec-
ognizes p38 MAPK (1:500; New England BioLabs).
Immunoblots were analyzed by densitometry using Bio-
profil BioLight PC software. Only film exposures that were
in the linear range of the ECL reaction were used for quan-
tification analysis.
Drug application
All drugs were applied by manually switching the super-
fusate. Drugs were diluted from stock solutions just before
application. CPA was prepared by first dissolving it in an
equimolar amount of HCl as a concentrated stock and
then diluting to its final concentration in aCSF. Other
drugs used in this study were dissolved in distilled water.
SB203580, SB239063 and CPA were purchased from Toc-
ris Cookson (Bristol, UK).
Statistical analysis
All data are expressed as means ± SEM and the statistic sig-
nificance was determined using the Mann-Whitney U-test
or Student's t-test. Numbers of experiments are indicated
by n. Probability values of p < 0.05 were considered to rep-
resent significant differences.
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